RECOMBINANT  POLYPEPTIDES  BASED  ON  C5A  PEPTIDASE  AS  POTENTIAL  VACCINE COMPONENTS AGAINST GROUP B STREPTOCOCCI

N. V. Duplik; I. V. Koroleva; K. B. Grabovskaya; A. N. Suvorov

doi:10.15789/1563-0625-2011-1-41-48

RECOMBINANT POLYPEPTIDES BASED ON C5A PEPTIDASE AS POTENTIAL VACCINE COMPONENTS AGAINST GROUP B STREPTOCOCCI

N. V. Duplik, I. V. Koroleva, K. B. Grabovskaya, A. N. Suvorov

https://doi.org/10.15789/1563-0625-2011-1-41-48

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Аbstract. Gene fragments encoding N-terminal and central parts of group B streptococci (GBS) C5a peptidase were cloned in E. coli M15. The appropriate recombinant SCPB1a and SCPB3a polypeptides with molecular masses of, resp., 12.0±0.5 kDa and 11.0±0.5 kDa, were subject to expression and affinity purification. Both polypeptides induced specific antibodies production upon subcutaneous immunization of mice. A more pronounced immune response was detected with SCPB3a injection. Antimicrobial properties of anti-SCPB1a and anti-SCPB3a antibodies have been investigated in vitro (by opsonophagocytosis test) and in vivo (a model of generalized GBS infection in mice). N-terminal and central segments of C5a peptidase molecule have been shown to contain epitopes inducing humoral immune response with production of class G antibodies that efficiently opsonize GBS, whereas recombinant SCPB1a and SCPB3a polypeptides can be recommended for future implications in development of a polycomponent vaccine against GBS. (Med. Immunol., 2011, vol. 13, N 1, pp 41-48)

Keywords

group B streptococci, C5a peptidase, recombinant polypeptides, immunogenicity, opsonophagocytosis

About the Authors

N. V. Duplik

Учреждение Российской академии медицинских наук Научно-исследовательский институт экспериментальной медицины Северо-Западного отделения РАМН, Санкт-Петербург
Russian Federation

I. V. Koroleva

K. B. Grabovskaya

A. N. Suvorov

References

1. Грабовская К.Б., Леонтьева Г.Ф., Мерингова Л.Ф., Воробьева Е.И., Суворов А.Н., Тотолян А.А. Протективные свойства некоторых поверхностных рекомбинантных полипептидов стрептококков группы В // ЖМЭИ. – 2007. – № 5. – С. 44-51.

2. Дуплик Н.В., Королева И.В., Суворов А.Н. Клонирование, экспрессия и изучение иммунологических свойств рекомбинантного полипептида на основе С5а пептидазы стрептококков группы В // Медицинская иммунология. – 2009. – Т. 11. – С. 7-14.

3. Мерингова Л.Ф., Войцеховский Б.Л., Духин А.И., Крамская Т.А., Поляк Р.Я. Применение методов химической кинетики для оценки аффинитета циркулирующих свободных и связанных с антигеном антител (модель экспериментальный грипп) // Иммунология. – 1986. – № 6. – С. 48-51.

4. Суворов А.Н., Грабовская К.Б., Леонтьева Г.Ф., Мерингова Л.Ф., Королева И.В., Дуплик Н.В., Тотолян А.А. Рекомбинантные фрагменты консервативных белков стрептококков группы В как основа специфической вакцины // ЖМЕИ. – 2010. – № 2. – С. 44-50.

5. Baker C.J., Edwards M.S. Group B streptococcal conjugate vaccines // Arch. DisChild. – 2003. – Vol. 88. – P. 375-378.

6. Beckmann C., Waggoner J.D., Harris T.O., Tamura G.S. and Rubens C.E. Identification of Novel Adhesins from Group B Streptococci by Use of Phage Display Reveals that C5a Peptidase Mediates Fibronectin Binding // Infect. Immun. – 2002. – Vol. 70. – P. 2869-2876.

7. Bohnsack J.F., Chang J.K. and Hill H.R. Restricted ability of Group B Streptococcal C5a-asa to anactivate C5a prepared from different animal species // Immun. – 1993. – Vol. 61. – P.1421 –1426.

8. Cheng Q., Stafslien D., Purushothaman S.S., Cleary P. The group B streptococcal C5a peptidase is both a specific protease and an invasion // Infect. Immun. – 2002. – Vol. 70. – P. 2408-2413.

9. Chmourigina I.I., Suvorov A.N., Ferrieri P., Cleary P.P. Conservation of the C5a peptidase genes in group A and B streptococci // Infect. Immun. – 1996. – Vol. 67. – P. 2387-2390.

10. Doran K.S., Nizet V. Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy // Mol. Microbiol. – 2004. – Vol. 54. – P. 23-31.

11. Edwards M. S. and Baker C.J. Group B streptococcal infections // Infectious diseases of the fetus and the newborn infant / Ed. Remington J.S. and J.O. Klein. – The W.B. Saunders Co., Philadelphia, Pa. – 2001. – P. 1091-1156.

12. Edwards M.S., Baker C.J. Group B streptococcal infections in elderly adults // Clin. Infect. Dis. – 2005. – Vol. 41. – P. 839-847.

13. Heath P.T., Balfour G.F., Tighe H., Verlander N.Q., Lamagni T.L., Efstratiou A.; HPA GBS Working Group. Group B streptococcal disease in infants: a case control study. // Arch. Dis. – Child. – 2009. – Vol. 94. – P. 674-680.

14. Jackson L.A., Hilsdon R., Farley M.M., Harrison L.H., Reingold A.L., Plikaytis. B.D., Wenger. J.D., Schuchat. A. Risk factors for. group. B streptococcal disease in adults // Ann. Intern. Med. – 1995. – Vol. 123. – P. 415-420.

15. Larsson C., Stalhammar-Carlemalm M. and Lindahl G. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine // Vaccine. – 1999. – Vol. 17. – P. 454-458.

16. Levent F., Baker C.J., Rench M.A., Edwards M.S. Early outcomes of group B streptococcal meningitis in the 21st century // Pediatr. Infect. Dis. J. – 2010.

17. Lowry O.H., Rosenbraugh N.J., Ferr A.L., Randall R.J. Protein measurement-with the folin phenol reagent // J. Mol. Biol. – 1957. – Vol. 193. – Р. 265-273.

18. Paoletti L.C., Wessels M.R., Rodewald A.K., Shroff A.A., Jennings H.J. and Kasper D.L. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharidetetanus toxoid conjugate vaccine // Infect. Immun. – 1994. – Vol. 62. – P. 3236-3243.

19. Takahahsi S., Nagano Y., Nagano N., Hayashi O., Taguchi F., Okuwaki Y. Role of C5a-asanin group B streptococcal resistance to opsonophagocytic killing // Infect. Immun. – 1995. – Vol. 63. – P. 4764-4769.

20. Yang H.H., Samantha J. Mascuch, Lawrence C. Madoff and Lawrence C. Paoletti. Recombinant Group B Streptococcus AlphaLike Protein 3 Is an Effective Immunogen and Carrier Protein // Clin. Vaccine Immunol. – 2008. – Vol. 15. – P. 1035-1041.

Review

For citations:

Duplik N.V., Koroleva I.V., Grabovskaya K.B., Suvorov A.N. RECOMBINANT POLYPEPTIDES BASED ON C5A PEPTIDASE AS POTENTIAL VACCINE COMPONENTS AGAINST GROUP B STREPTOCOCCI. Medical Immunology (Russia). 2011;13(1):41-48. (In Russ.) https://doi.org/10.15789/1563-0625-2011-1-41-48

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Medical Immunology (Russia)